Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.

Category Primary study
JournalJournal of Clinical Oncology
Year 2007
This article has no abstract
Epistemonikos ID: 9c85be795854ac0874881a0be5a6b17fcf0310ac
First added on: Apr 04, 2025